20
Participants
Start Date
October 31, 2012
Primary Completion Date
December 31, 2012
Study Completion Date
April 30, 2014
octreotide
Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
DG3173
Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Lead Sponsor
Aspireo Pharmaceuticals Limited
INDUSTRY